Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Meiragtx Holdings ( (MGTX) ).
On April 16, 2026, MeiraGTx Holdings plc entered into an underwriting agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC for a public offering of 11,111,111 ordinary shares at $9.00 per share, with all shares sold by the company. The offering, expected to close on April 17, 2026 subject to customary conditions, is anticipated to generate approximately $93.3 million in net proceeds for MeiraGTx.
The company plans to use the funds for general corporate purposes, including working capital and capital expenditures, and believes the proceeds, together with existing cash, will finance operations and capital needs into the second half of 2028. This capital raise is expected to support potential commercial launches of its lead gene therapy candidates, bota-vec and AAV-hAQP1, if they receive regulatory approval, strengthening MeiraGTx’s ability to advance toward commercialization in its target markets.
The most recent analyst rating on (MGTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.
Spark’s Take on MGTX Stock
According to Spark, TipRanks’ AI Analyst, MGTX is a Neutral.
The score is held down primarily by weak financial quality—persistent losses, continued cash burn, and a weakened capital structure with negative equity. Offsetting this are strong technical momentum and positive pipeline/strategic corporate developments, while valuation remains difficult to support given negative earnings and no dividend data.
To see Spark’s full report on MGTX stock, click here.
More about Meiragtx Holdings
MeiraGTx Holdings plc is a biotechnology company focused on developing gene therapies, including product candidates such as bota-vec for X-linked retinitis pigmentosa and AAV-hAQP1 for radiation-induced xerostomia. The company targets serious ophthalmologic and salivary gland conditions, positioning itself within the advanced therapeutics and gene therapy market.
Average Trading Volume: 497,099
Technical Sentiment Signal: Buy
Current Market Cap: $916.3M
Learn more about MGTX stock on TipRanks’ Stock Analysis page.